biopolymers-bioplastics-2017-posters-abstracts

8 / 32

Page 60
Notes:
conferenceseries .com
Volume 8, Issue 6 (Suppl) J Bioremediat Biodegrad, an open access journal
ISSN:2155-6199 Biopolymers & Bioplastics 2017
October 19-20, 2017
October 19-20, 2017 San Francisco, USA
7th International Conference and Exhibition on
Biopolymers and Bioplastics
Biocompatible poly(Aspartic Acid) derivative-coated USPIO nanoparticles incorporated with anticancer
drug for theranostic applications
Hasoo Seong
Korea Research Institute of Chemical Technology, Republic of Korea
As a theranostic MRI contrast agent with high relaxivity, USPIONP (ultrasmall superparamagnetic iron oxide nanoparticle) was
prepared and characterized. The USPIONP was composed of an IONP core, amphiphilic poly(aspartic acid) copolymer (P) shell
and an anticancer drug, epirubicin (EPI). The polymer P, poly(2-hydroxyethyl aspartamide)-C16-mPEG, was synthesized using a ring-
opening reaction of polysuccinimide. The polymer P-coated IONP (P-IONP) was prepared via synthesis of IONP and coating of P
on the IONP by using co-precipitation method. The P-IONP was a USPIONP having a hydrodynamic diameter of about 40 nm. EPI-
loaded USPIO (EPI-USPIO) had a hydrodynamic diameter of about 50 nm. Notably high T2 relaxivity of EPI-USPIO corresponded to
MR contrast enhancement 2.7-fold compared with a commercial contrast agent. The relaxivity was proportional to EPI encapsulation
efficiency of the EPI-USPIO. The encapsulated EPI was released from EPI-USPIONP in a sustained manner. USPIONP had no
cytotoxicity against HeLa cells, whereas EPI-USPIONP showed cytotoxicity increasing in an EPI dose-dependent manner. Flow
cytometry revealed that cellular uptake of EPI from EPI-USPIONP was comparable to free EPI and confocal microscopy showed
nuclear uptake of EPI from EPI-USPIONP. These results suggest that USPIONP is a promising theranostic platform whose MR
contrast enhancement can be controlled by modulating encapsulation efficiency of the therapeutics.
Biography
Hasoo Seong has completed his PhD from Seoul National University and postdoctoral studies from Purdue University. He is a senior research scientist in Bio &
Drug Discovery Division of Korea Research Institute of Chemical Technology, an organization supported by South Korea Government. He has his expertise in the
field of drug delivery system and biomaterials.
Hasoo Seong, J Bioremediat Biodegrad 2017, 8:6 (Suppl)
DOI: 10.4172/2155-6199-C1-012